FilingReader Intelligence
Alembic Pharmaceuticals gains US approval for carbamazepine tablets
July 26, 2025 at 06:19 AM UTC•By FilingReader AI
Alembic Pharmaceuticals announced US FDA final approval for its Carbamazepine Extended-Release Tablets in 100mg, 200mg, and 400mg strengths, the generic equivalent of Novartis's Tegretol-XR.
The market size for these tablets is estimated at $71m for the twelve months ending March 2025. This brings Alembic's total US FDA approvals to 225.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:APLLTD•Bombay Stock Exchange
News Alerts
Get instant email alerts when ALEMBIC PHARMACEUTICALS publishes news
Free account required • Unsubscribe anytime